2020
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center
Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, Trippa L, Lin NU, Winer EP, King TA. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Research And Treatment 2020, 185: 215-227. PMID: 32939592, DOI: 10.1007/s10549-020-05931-9.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalPN1 breast cancerRecurrence scoreChemotherapy useBreast cancerOverall survivalChemotherapy receiptPN1 patientsRS testingUse of RSNode-positive breast cancerOncotype DX recurrence scoreAdjuvant chemotherapy receiptLow genomic riskNode-positive diseaseAdjuvant treatment decisionsLow recurrence scoreShort-term outcomesMultivariate logistic regressionComprehensive cancer centerDX recurrence scoreOncotype DX testingChemotherapy omissionPT1-2N0Upfront surgery
2013
High performance teamwork training and systems redesign in outpatient oncology
Bunnell CA, Gross AH, Weingart SN, Kalfin MJ, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S. High performance teamwork training and systems redesign in outpatient oncology. BMJ Quality & Safety 2013, 22: 405. PMID: 23349386, DOI: 10.1136/bmjqs-2012-000948.Peer-Reviewed Original ResearchConceptsBreast cancer programCoordination of carePatient satisfaction scoresComprehensive cancer centerDays of treatmentSafety of careOncology careCancer CenterCare coordinationCancer programsInfusion nursesPatients' perceptionsOutpatient oncologyTreatment daysMost cliniciansPhysician appointmentsAmbulatory settingInsufficient statistical powerPatient issuesSatisfaction scoresClinic observationsHigh-risk areasTeam member rolesCareTrainer model